Market Overview

BlissCo Earns Pre-Sales License Inspection from Health Canada


Not for distribution in the U.S. or to U.S. Newswires

VANCOUVER, British Columbia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- BlissCo Cannabis Corp.  (CSE:BLIS) (FRA: GQ4B), ("BlissCo") or the ("Company") is pleased to announce that it will complete a pre-sales license inspection from Health Canada in September 2018.

"Health Canada has completed their paper-based review of our application to amend our ACMPR license to include the sale of dried cannabis, and we are excited to announce that our inspection will be completed in September," said BlissCo CEO, Damian Kettlewell. "Our team is aligned and focused on successfully completing our multi-day, pre-sales inspection and we are cautiously optimistic that we will earn our dried cannabis sales license in November so that we can hit the ground running following legalization."

The BlissCo team has been focused on scaling up its operations in preparation for commercialization by securing its oil production license, developing an e-commerce strategy, building its network of partners and other high-impact initiatives.

"Dried cannabis products will represent BlissCo's first chapter of commercialization; future products will be diversified but continue to be wellness-focused. The large majority of our sales within a few years will be from cannabis oil tinctures, capsules, sublingual sprays, concentrates and edibles, with mixed ratios of CBD and THC," said Kettlewell.

About BlissCo Cannabis Corp.
BlissCo Cannabis Corp. (CSE:BLIS) (FRA: GQ4B) is an ACMPR licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships. 

BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets.

BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo's future patients and customers.

Learn more:

On Behalf of the Board of Directors


Damian Kettlewell, CEO, Founder & Chair

For further information please contact:

Ariel Jack Lewinski, Business Development & Investor Relations

# 1-604-377-7533

Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"). The use of any of the word "will" and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. 


View Comments and Join the Discussion!